Tandem Diabetes Care (NASDAQ:TNDM) has received an average rating of “Buy” from the ten brokerages that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $8.63.
Several research firms have commented on TNDM. ValuEngine raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating in a research report on Monday. Piper Jaffray raised shares of Tandem Diabetes Care from a “neutral” rating to an “overweight” rating in a research report on Monday. Zacks Investment Research downgraded shares of Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research report on Thursday, May 3rd. BidaskClub raised shares of Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, April 11th. Finally, Oppenheimer set a $8.00 target price on shares of Tandem Diabetes Care and gave the stock a “buy” rating in a research report on Friday, April 6th.
In other Tandem Diabetes Care news, Director Dick Allen purchased 25,539 shares of the stock in a transaction dated Tuesday, March 6th. The shares were bought at an average cost of $3.88 per share, with a total value of $99,091.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 9.30% of the company’s stock.
NASDAQ TNDM opened at $11.75 on Friday. Tandem Diabetes Care has a 1-year low of $11.61 and a 1-year high of $11.90. The company has a debt-to-equity ratio of 6.45, a quick ratio of 2.01 and a current ratio of 2.62. The firm has a market capitalization of $558.01 million, a PE ratio of -0.92 and a beta of -0.40.
Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Thursday, March 1st. The medical device company reported ($1.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.10) by ($0.13). The firm had revenue of $40.00 million for the quarter, compared to analyst estimates of $38.41 million. During the same quarter in the previous year, the business earned ($0.48) earnings per share. The company’s revenue was up 61.3% compared to the same quarter last year. sell-side analysts predict that Tandem Diabetes Care will post -1.47 EPS for the current year.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company, which designs, develops and commercializes products for people with insulin dependent diabetes. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.